The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
To own Centene, you generally need to believe that it can restore underwriting discipline in its exchange and Medicaid books while managing policy risk around subsidies and rates. The latest guidance cut directly pressures the main short term catalyst, a clear earnings recovery, and reinforces the biggest near term risk: utilization and reimbursement moving in the wrong direction at the same time.
The company’s updated full year 2025 outlook, now calling for a GAAP diluted loss per share not exceeding US$12.85, brings that profit recovery question into sharper focus. It ties the heavier exchange utilization and Medicaid rate issues to a concrete financial reset and gives investors a reference point to judge whether future utilization trends and rate negotiations are actually improving or merely stabilizing at a weaker level.
Yet behind the headline loss guidance, one risk investors should be aware of is how potential subsidy changes could reshape Centene’s exchange membership and...
Read the full narrative on Centene (it's free!)
Centene's narrative projects $195.6 billion revenue and $2.1 billion earnings by 2028. This requires 7.0% yearly revenue growth with earnings remaining flat from $2.1 billion today.
Uncover how Centene's forecasts yield a $39.41 fair value, in line with its current price.
Sixteen fair value estimates from the Simply Wall St Community span roughly US$31.58 to US$191.51, showing just how far apart views on Centene sit. When you set that spread against the recent cut to earnings guidance driven by higher exchange utilization and Medicaid rate uncertainty, it underlines why many market participants are rethinking what a sustainable profit profile here might look like and why it can pay to review several viewpoints before forming your own.
Explore 16 other fair value estimates on Centene - why the stock might be worth 19% less than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com